Jeffrey Eisele, Chief Development Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 1,291 shares at $30.43 ($39K) on 2025-01-22, disclosed to the SEC on 2025-01-23.
Seasonal sale ($39k) by Chief Development Officer — this insider has traded APLS in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| APLS | SELL | 2024-12-27 | $2K | — | Filing → |
| APLS | SELL | 2024-01-31 | $145K | — | Filing → |
| APLS | SELL | 2024-01-24 | $940K | — | Filing → |